collection of positive quotes for holders

Just a collection of random findings I thought might make CXS holders more positive, in light of a negative vibe.

FROM THE 22nd committee meeting...
DR. ECKHARDT:
"I say that because I think most of us feel that the T315I mutation is the Holy Grail of CML and clearly, no one wants to hinder a drug being developed in that population."

AmoyDX has yet another ABL T315I Mutation Detection Kit. A quote from the product page;
"Easy Standardization - General PCR lab could perform, technicians could obtain reproducible results without special training, which facilitate standardized management;"
REF: http://www.amoydx.com/en/goods-22-ABL+T315I+Mutation+Detection+Kit.html

A 2006 article titled "Dasatinib Proves Effective in CML in Phase II Trial"...note the finding that patients whom receive 2nd line TKI treatment such as dasatinib, with the T315i mutation, appear to have a worse outcome than those with other mutations. Also note that the identification
and of patients with the T351I mutation has been a well eastablished and documented test in medical lit for years.
"The good news, Dr. Sawyers said, is that patients who carry such mutations do not have a worse clinical outcome on dasatinib than do the patients without mutations, except for the 19 patients with the T351I mutation.
Resistance information and genotyping information is not available for the entire Phase II cohort. But looking at just the patients treated at UCLA, the researchers found seven non-responders with the T315I."
REF: http://journals.lww.com/oncology-times/Fulltext/2006/06100/Dasatinib_Proves_Effective_in_CML_in_Phase_II.18.aspx

And lastly, just how urgent T351I really is - as we already well know ;) Chemgenex does have fast track status, so....
"However, one particular mutant form of BCR-ABL, the T351I mutation, is resistant to all approved agents and is a major hurdle yet to be overcome."
REF: http://www.cancerforum.org.au/Issues/2008/November/Forum/Targeted_therapies_in_haematolgical_malignancies.htm